Figure 4.

G28 compound inhibits FASN activity in Gefitinib Resistant (GR) models. Cells were treated for 72 h with EGCG or G28 at a concentration equal to their IC₅₀ and with DMSO as control. FASN activity was assayed by counting radiolabeled fatty acids synthesized de novo. Bars represent the remaining activity as a percentage in treated versus untreated cells (control, Ctrl). Data are mean ± SE from at least three independent experiments. ** p < 0.010, *** p < 0.001 indicate levels of statistically significance.